Publications

Date : 12-18-20

bloomberg podcast

Bloomberg Radio

BioMediCan Founder and CEO on Artificial-Cannabinoids (Podcast)

Max Mikheev, Founder and CEO at BioMediCan, discusses the business and benefits of artificial-cannabinoids.

Date : 12-16-20

benzinga

Mj.com

Biomedican successfully biosynthesizes two rare cannabinoids

“The global demand for rare cannabinoids is growing astronomically,” said Biomedican CEO Maxim Mikheev. “We are fully confident we will have the highest quality and lowest cost product in the market.”

Date : 12-10-20

PA_Biomedican_Banner

Pharma Almanac

Leveraging Biosynthesis to Create Pure Cannabinoids for Less

Biosynthesis of rare cannabinoids is one of the fastest growing markets in the world today, and BIOMEDICAN is uniquely positioned with what we believe are the best intellectual property and results in the space.  CBG/CBGA represents the next generation of many new cannabinoids we will be taking to market, and we are fully confident we will have the highest quality, highest yields, and lowest-cost product on the market, which we believe will make us the market leader in the months and years to come.

Date : 12-04-20

Biomedican's

Nutra Ingrediants

Startup claims fermentation expertise will provide differentiator in production of rare cannabinoids

O’Neill said that while other companies are advertising the capability of producing minor cannabinoids like CBG, in his view the volumes and the pricing of those ingredients will not be competitive with BioMedican’s platform.

“We purposefully stayed away from CBD. Prices have collapsed and it has become a commoditized market full of me-too products,” he said.

Date : 11-28-20

Weed-Under-Magnifyer-Magenta-1920x970

El Planteo

THCV: the New Cannabinoid that will Conquer the Industry

Fortunately, recent innovations in biosynthesis are making THCV easier to produce than ever. Now cannabinoids can be synthesized without plants, resulting in shorter production cycles, less work and energy, and higher yields . The end result is a non-GMO, pharmaceutical grade organic product that is 70-90% cheaper than wholesale prices. Biosynthesis is also more sustainable than plants, since it uses 90% less natural resources and energy.

Date : 12-04-20

benzinga

Benzinga

THCV: The Rare Cannabinoid That’ll Conquer The Industry

THCV produced through biosynthesis can also be added to any edible with zero modifications, which will give it a major advantage in the food and beverage industry. Health food companies will be able to add THCV to a variety of foods and beverages, including protein bars, chocolates, cereals, granola bars, and sports drinks.

Date : 11-27-20

Biomedican lab

Westword

CBYeast: Biotech Companies Are Pulling Cannabinoids from Yeast

One biotech company is looking to shake up the cannabinoid-product industry by using biosynthesis to produce rare cannabinoids at a fraction of their current price.

Employing a specialized strain of yeast called Yarrowia lipolytica, California company Biomedican extracts pharmaceutical-grade cannabinoids that are biologically identical to those extracted from plants…

Westword spoke with Biomedican president Dennis O’Neill and CEO Max Mikheev.

Date : 11-18-20

Biomedican on Healthcare Business Today

Healthcare Business Today

How Rare Cannabinoids are Disrupting the Pharmaceutical Industry

The global cannabinoid market will take a significant toll on the environment. A kilogram of cannabis releases roughly the same amount of carbon dioxide emissions into the atmosphere as three million U.S. cars. Biosynthesis is at the forefront of a safer, more efficient, and environmentally friendly way to produce rare cannabinoids.

Biomedican has developed a patented method of cannabinoid biosynthesis production from proprietary yeasts. This process produces 100% pure rare cannabinoids without cultivating plants, resulting in cheaper, faster, and more environmentally friendly results.

Date : 11-9-20

Biomedican on Benzinga

Yahoo! Finance (Benzinga pick-up)

Is the Cannabis Market Ready for Lab-Grown Cannabinoids?

“We’re not competing with anybody that’s in that grow, harvest, extract and purify business,” says Biomedican CFO Dennis O’Neill.

The biotech company uses a genetically-modified, proprietary version of yeast to produce cannabinoids without the need for cannabis plants. The resulting cannabinoids are said to be bio-identical to the molecules that can be found in nature.

“We produce 99% pharmaceutical grade products,” says O’Neill. While the method used by Biomedican employs GMO yeast, the final product does not contain any of it, which is why the company can claim its cannabinoids are organic and GMO-free.

Date : 11-6-20

Biomedican on Proactive Investors

Proactive Investors

Biomedican Inc’s organic, non-GMO CBD compound set for large scale production in 2021

Biomedican Inc Chief Investment Officer Dennis O’Neill tells Proactive the Fremont, California-based CBD-focused group is focusing on commercializing its organic, non-GMO CBD compound.

O’Neill says because its CBD product produces 0.0% THC, it opens up distribution channels for the group. The group is expected to begin large-scale production in 2021.

Date : 10-30-20

2020-10-15T171124Z_3_LYNXMPEG9E1KC_RTROPTP_4_USA-STOCKS-CANNABIS-1024x683

Inquirer.Net (Reuters pick-up)

Cannabis companies, betting on a Biden win, ready IPOs

“Biosynthetic cannabinoid maker Biomedican has also laid out plans to go public in the first half of 2021″

Date : 10-29-20

1603745421-GettyImages-1208615656

Green Entrepreneur (Reuters pick-up)

Synthetic Cannabis Could Disrupt The Marijuana Industry In A Big Way

“By creating biosynthetic cannabis compounds, companies also skip any issues using the real cannabis plant, which remains illegal at the federal level. And the costs are dramatically lower. Biomedican, a company that is working in this area, claims that they have 70 to 90 percent lower production costs than cannabis farms.”

Date : 10-27-20

Biomedican on NJ.com

NJ.com

This week’s most important N.J. cannabis stories: Industry event featuring Booker, hemp goes to backburner, what employers should know

“All the federal and state regulations are around touching the plant and producing THC at any point in time,” said Dennis O’Neill, chief investment officer of California-based Biomedican. “That creates a big opportunity for us because these rare cannabinoids are the next generations of CBGs.”

Date : 10-26-20

42198adda8cc56c4cb320e4c7f0823f64b7d06be-1000x527

Drug Topics

How Rare Cannabinoids Are Disrupting the Pharmaceutical Industry

“Rare cannabinoids like CBG/CBGA, CBN/CBNA, THCV/THCVA, and THCA all have significant evidence of major health benefits. For example, there have been many clinical trials on CBG/CBGA indicating its potential to help fight inflammation, pain, and nausea.”  Maxim Mikheev, CEO and Founder of Biomedican, a biotech startup designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts.

Date : 10-16-20

10-16-20-biden-ipos

Ganjaprenerr (Reuters pick-up)

Cannabis Firms Consider IPOs Anticipating a Biden Presidency

Multiple hemp and cannabis firms say they are planning initial public offerings under the assumption that Joe Biden will win the presidential election next month.

Date : 10-15-20

download

Reuters

Cannabis companies, betting on a Biden win, ready IPOs

NEW YORK (Reuters) – A year ago, Flora Growth Chief Executive Damian Lopez had just spent a chunk of his company’s seed capital buying a Colombian cannabis producer, and was fighting his way through the legal and financial hurdles that have made development of the industry such a challenge over the past decade.

Date : 10-12-20

flowers-2469212_1920_38

Benzinga

Cannabinoids Beyond THC And CBD Pique Market Interest

Dennis O’Neill, co-founder and CIO of California-based biotech startup Biomedican elaborated: “[CBD and THC] are known because plants can produce them in large quantities, which makes them significantly more affordable.”

Date : 10-8-20

2QTN2FQVXNHJNKSBCZP2WRO6Y4

The Philadelphia Inquirer

The race is on for synthetic cannabinoids

“Right now, making CBD means you’re in the farming business. By the time you harvest and extract and factor in the purification, it’s expensive,” said Dennis O’Neill, Biomedican‘s chief investment officer. “And you can’t even produce the exact same product every time.”

Date : 10-8-20

shutterstock_731598136-e1602095010978

Dope Magazine (Bloomberg pick-up)

Synthetically-Produced Cannabinoids Could Soon Become a New Normal

Fremont, California-based Biomedican has the means to produce CBG in large quantities.  “Right now, making CBD means you’re in the farming business,” Dennis O’Neill, Biomedican’s chief investment officer, told Bloomberg. “By the time you harvest and extract and factor in purification, it’s expensive. And you can’t even produce the exact same product every year.”

Date : 10-4-20

Biomedican on Bloomberg

Bloomberg

Race Is On for Synthetic Cannabinoids: Cannabis Weekly

Biomedican says it will soon be able to produce multiple strains at a similar cost [under $1 a gram], far below CBG’s current wholesale price of $20 a gram. “This is the next generation of CBD,” Dennis O’Neill said.

Date : 9-28-20

Biomedican on Nasdaq

Nasdaq

Why CBG and Other Rare Cannabinoids Will Supplant CBD

“CBD will become an afterthought as more potent cannabinoids replace it in medicine, beauty products, food and beverages, and more. Rare cannabinoids like CBG, THCA, CBN, THCV, and more will all contribute to this shift, with CBG being the most highly desired for its versatile applications in both the pharmaceutical and food/beverage industries.” Maxim Mikheev, CEO and Founder of Biomedican, a biotech startup designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts.

Date : 9-17-20

Biomedican on Forbes

Forbes

Move Over CBD: Rare Cannabinoids Shaking Up Cannabis And Hemp Products

“According to Dennis O’Neill, chief investment officer at Biomedican, when it comes to producing rare cannabinoids, the grow-harvest-extract method is not only costly; it’s unreliable. Instead, the firm uses biosynthesis, a natural process that O’Neill likens to brewing beer, to grow rare pharmaceutical-grade cannabinoids at scale.”

Date : 9-12-20

1599920380652

Axios

Startups want to biosynthesize CBD

Biosynthesis companies will be able to produce expensive cannabinoids at a much lower price and without fears of contamination. “We can harvest every day, as opposed to a plant that requires 55 days to grow,” says Dennis O’Neill, chief investment officer at Biomedican – biotech startup.

Date : 9-8-20

plants-without-the-plant-575-web

Biofuels Digest

Plants without the plant? A look at cannabinoids made with yeasts instead of plants

“Biomedican developed a unique method of cannabinoid biosynthesis production from proprietary yeasts. This process produces high-quality rare cannabinoids without plants, resulting in cheaper, faster, and more sustainable results.”

Press Releases

Date : 12-02-20

Biomedican Enters the Global Astaxanthin Market Through Its Patented Biosynthesis Platform

SAN FRANCISCODec. 2, 2020 /PRNewswire/ — BIOMEDICAN, a biotech company designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new development allows BIOMEDICAN’s biosynthesis platform to target any high-value compound and significantly disrupt the current technologies.

Date : 11-19-20

Biomedican Announces Organic Biosynthesis of Rare Cannabinoid THCV/THCVA

SAN FRANCISCONov. 19, 2020 /PRNewswire/ — BIOMEDICAN, a biotech company designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts, has successfully biosynthesized rare cannabinoid THCV/THCVA. The product is pharmaceutical- grade, 100% organic, non-GMO, and bioidentical to the molecules occurring in nature, with production costs that are over 90% less than current wholesale prices.

Date : 11-12-20

Biomedican Announces Successful Biosynthesis and Large-Scale Production of Rare Cannabinoids CBG/CBGA

Fremont, CA — Biomedican, a biotech company designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts, has successfully biosynthesized rare cannabinoid CBG/CBGA and is setting up large-scale production. The product is pharmaceutical-grade, contains zero toxins and contaminants, and is 75-90% less expensive than current wholesale prices. Biomedican will be ready to ship CBG/CBGA in Q3-Q4 2021.

Date : 11-10-20

Full Spectrum Biosciences, Biomedican to Produce Yeast-Based Cannabinoids

LOS ANGELES – Agritek Holdings, Inc. (AGTK), a fully integrated, active real estate investor and its wholly-owned subsidiary Full Spectrum Biosciences Inc., an IP, formulation, and white label provider for popular hemp brands RehabRx and Hemp Pops, today announced that Full Spectrum Biosciences and California based Biomedican Inc. have executed a Letter of Intent and are completing a joint venture agreement for the first test pilot program using Biomedican’s patented biosynthetic methods using yeast fermentation, to ensure the efficient production of high-quality cannabinoid profiles and compounds.

Date : 11-6-20

Biomedican Inc’s organic, non-GMO CBD compound set for large-scale production in 2021

Biomedican Inc Chief Investment Officer Dennis O’Neill tells Proactive the Fremont, California-based CBD-focused group is focusing on commercializing its organic, non-GMO CBD compound.

Date : 11-5-20

Rising High: An exclusive talk with biosynthesis company Biomedican

In this edition of “Rising High,” The Fly conducted an exclusive interview with Dennis O’Neill, chief investment officer of Biomedican, a producer of pharmaceutical-grade compounds using natural biological synthesis.